Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Matthieu Gracia"'
Autor:
Tristan Mangeat, Matthieu Gracia, Alexandre Pichard, Sophie Poty, Pierre Martineau, Bruno Robert, Emmanuel Deshayes
Publikováno v:
EJNMMI Research, Vol 13, Iss 1, Pp 1-6 (2023)
Abstract Background Radiolabeled-antibodies usually display non-specific liver accumulation that may impair image analysis and antibody biodistribution. Here, we investigated whether Fc silencing influenced antibody biodistribution. We compared recom
Externí odkaz:
https://doaj.org/article/ef2f33b9aff744cb8b78af90bd6122a6
Autor:
Fanny Leenhardt, Frédéric Fiteni, Ludovic Gauthier, Marie Alexandre, Séverine Guiu, Nelly Firmin, Stéphane Pouderoux, Marie Viala, Gerald Lossaint, Chloé Gautier, Caroline Mollevi, Matthieu Gracia, Celine Gongora, Litaty Mbatchi, Alexandre Evrard, William Jacot
Publikováno v:
Pharmaceutics, Vol 14, Iss 4, p 841 (2022)
Palbociclib is a good candidate for therapeutic drug monitoring (TDM) due to its narrow therapeutic range and frequency of toxicities, particularly high-grade neutropenia. In this prospective, bicentric clinical trial, we evaluated the palbociclib ex
Externí odkaz:
https://doaj.org/article/d52b956fb3394cc7bed5973cee308283
Autor:
Fanny Leenhardt, Bénédicte Marion, Claudia Muracciole-Bich, Stéphane Pouderoux, Alexandre Evrard, Catherine Perrin, Céline Roques, Litaty Mbatchi, Marie Alexandre, William Jacot, Céline Gongora, Matthieu Gracia, Nelly Firmin
Publikováno v:
Cancer Research. 81:PS5-16
Background: The CDK4/6 inhibitors palbociclib is prescribed in association with hormonal therapy for the management of metastatic breast cancer patients. Like most oral targeted drug, therapeutic drug monitoring may be used for personalize their dosa
Publikováno v:
médecine/sciences. 36:56-60
L’immunothérapie à base d’anticorps monoclonaux (AcM) connaît un plein essor en cancérologie. En 2020, plus de 40% des anticorps approuvés par la FDA (Food and Drug Administration) (34 sur 84 anticorps, selon The Antibody Society) ont une in
Autor:
Nicolas Joubert, Aubin Pitiot, Nathalie Heuzé-Vourc'h, Matthieu Gracia, Caroline Denevault-Sabourin, Timothée Blin, Thomas Sécher, Jean-Pierre Pouget, Juliette Lamamy, Sophie Poty, Valérie Gouilleux-Gruart, Débora Lanznaster, Yara Al Ojaimi
Publikováno v:
Pharmacology and Therapeutics
Pharmacology and Therapeutics, 2021, pp.108022. ⟨10.1016/j.pharmthera.2021.108022⟩
Pharmacology & Therapeutics
Pharmacology and Therapeutics, Elsevier, 2021, pp.108022. ⟨10.1016/j.pharmthera.2021.108022⟩
Pharmacology and Therapeutics, 2021, pp.108022. ⟨10.1016/j.pharmthera.2021.108022⟩
Pharmacology & Therapeutics
Pharmacology and Therapeutics, Elsevier, 2021, pp.108022. ⟨10.1016/j.pharmthera.2021.108022⟩
International audience; Antibody-based therapeutics have become a major class of therapeutics with over 120 recombinant antibodies approved or under review in the EU or US. This therapeutic class has experienced a remarkable expansion with an expecte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6ee69ea99fbe731deecbad7ca213160
https://hal.science/hal-03531953
https://hal.science/hal-03531953
Publikováno v:
Medecine sciences : M/S.
Monoclonal antibody (mAb)-based immunotherapy is booming in oncology. In 2020, more than 40% of FDA (Food and Drug Administration)-approved antibodies (34 out of 84 antibodies, according to The Antibody Society) have an indication for cancer therapy.
Autor:
Alexandre Evrard, Fanny Leenhardt, Marie Alexandre, Nelly Firmin, William Jacot, Bénédicte Marion, Céline Gongora, S Pouderoux, Celine Roques, Catherine Perrin, Claudia Muracciole-Bich, Matthieu Gracia, Litaty Mbatchi
Publikováno v:
Journal of Pharmaceutical and Biomedical Analysis
Journal of Pharmaceutical and Biomedical Analysis, 2020, 188, pp.113438. ⟨10.1016/j.jpba.2020.113438⟩
Journal of Pharmaceutical and Biomedical Analysis, Elsevier, 2020, 188, pp.113438. ⟨10.1016/j.jpba.2020.113438⟩
Journal of Pharmaceutical and Biomedical Analysis, 2020, 188, pp.113438. ⟨10.1016/j.jpba.2020.113438⟩
Journal of Pharmaceutical and Biomedical Analysis, Elsevier, 2020, 188, pp.113438. ⟨10.1016/j.jpba.2020.113438⟩
The CDK4/6 inhibitors palbociclib and ribociclib are kinase inhibitors used in association with hormonal therapy for the management of patients with metastatic breast cancer. Like most kinase inhibitors, therapeutic drug monitoring may be used for pe